Bristol Myers Raises Revenue Forecast and Lowers EPS
Bristol Myers Squibb raised its full-year revenue outlook on strong sales of newer medicines while lowering its earnings projection due to an acquisition-related charge. Third-quarter revenue and adjusted profit both topped Wall Street estimates.
Xurve View
Insights:
Xurve View
BRISTOL-MYERS SQUIBB CO raised its full-year revenue outlook to $50.25B on Thursday while lowering its 2026 EPS forecast to $6.35 following an acquisition charge. The United States drugmaker adjusted guidance as newer medicine sales surged 12% over the prior year. Investors pushed shares up 2.3% in premarket trading following the beat on third-quarter estimates.
